<DOC>
	<DOCNO>NCT02687867</DOCNO>
	<brief_summary>To obtain good understand comparative effectiveness dabigatran versus Vitamin K antagonist ( VKA ) stroke prevention patient Non-valvular atrial fibrillation ( NVAF ) real-life setting .</brief_summary>
	<brief_title>Real-world Comparative Effectiveness Dabigatran Versus Vitamin K Antagonist</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Nonvalvular atrial fibrillation define occurrence 2 inpatient outpatient claim ICD9 427.31 ( International Classification Disease , Ninth Revision , Clinical Modification ) diagnosis code time patient 's data history prior inclusion Patients require 180 day enrollment assessment baseline characteristic CHA2DS2Vasc ( Diabetes mellitus ; S2 : prior Stroke TIA Thromboembolism ; V : Vascular disease ; A : Age 6574 year ; Sc : Sex category ) score â‰¥2 180 day prior index dabigatran use baseline period Patients &lt; 18 year age Patients valvular Atrial fibrillation Pregnancy Malignant cancer Transient cause Atrial fibrillation Patients Venous thromboembolism ( pulmonary embolism Deep Vein Thrombosis ) Patients major surgery define hip knee replacement Prescriptions Oral anticoagulant ( OACs ) { apixaban , warfarin , dabigatran , rivaroxaban } index date Prescription one OAC index date Patient event define composite endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation ( NVAF )</keyword>
	<keyword>Prevention</keyword>
	<keyword>Stroke</keyword>
</DOC>